← Human Trials & Peer-Reviewed Studies
Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
Plain-language guide to PMID 35834254 (2022): observational study of Angiotensin II, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 35834254
- Journal
- JAMA network open
- Year
- 2022
- Study type
- Observational Study
- Authors
- Cohen JB et al. (17 authors)
- DOI
- 10.1001/jamanetworkopen.2022.20680
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II in the context of low blood pressure and orthostatic hypotension, published as an observational study.
To emulate a target trial to evaluate the cognitive outcomes of initiating an ARB- vs ACEI-based antihypertensive regimen in individuals at risk for mild cognitive impairment (MCI) and probable dementia (PD).
Why It Was Studied
The cardiovascular and renal outcomes of angiotensin-II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) treatment are well-known; however, few studies have evaluated initiation of these agents and cognitive impairment.
New users of ARB vs ACEI during the first 12 months of trial follow-up.
Who Took Part
PubMed indexes the participants as adults and older adults, both men and women.
Participants were using neither an ARB nor ACEI at baseline.
How the Study Was Run
Active comparator, new-user observational cohort study design using data from the Systolic Blood Pressure Intervention Trial (SPRINT), conducted November 2010 through July 2018.
Data analysis was conducted from April 7, 2021, to April 26, 2022.
What Was Measured
The cardiovascular and renal outcomes of angiotensin-II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) treatment are well-known; however, few studies have evaluated initiation of these agents and cognitive impairment.
The subject headings attached to it are Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Cognitive Dysfunction, Dementia and Proportional Hazards Models.
What This Means in Plain Language
This is an observational study of Angiotensin II in people with low blood pressure and orthostatic hypotension.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (JAMA network open), a journal based in United States.
More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.